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Abstract 
 The objective of this master thesis is to evaluate the impact of CSR measures in the 
financial performance of the European pharmaceutical industry. By definition, CSR measures 
is quantified as corporate social disclosure considering the published CSR keywords on the 
annual reports of the selected companies, over four fiscal years (2010-2013). The financial 
performance of the companies were measured as return on assets (ROA) and Tobin’s Q. In 
order to defend the hypothesis developed, a multivariate regression is performed. The results 
obtained show no significant impact on the financial performance of a company nor in the 
short-time, nor in the long-time. Moreover, by comparison with other studies, it was possible 
to conclude that the financial performance is differently affected when considering different 
industries.  
 
Introduction 
 Nowadays, no major company can survive without a statement on corporate social 
responsibility (CSR). In the last forty years of the twentieth century, corporate social 
responsibility became one of the hot topics in the management academic literature (Anderson 
and Frankle, 1980). Part of the debate that surrounds the studies on CSR is due to the existence 
of various definitions of this concept. Several definitions were developed, as different 
stakeholders see the role of the firms in society differently (Giannarakis and Theotokas, 2011). 
The modern concept of CSR - “corporate social responsibility involves the conduct of a 
business so that it is economically profitable, law abiding, ethical and socially supportive. To 
be socially responsible then means that profitability and obedience to the law are foremost 
conditions when discussing the firm’s ethics and the extent to which it supports the society in 
which it exists with contributions of money, time and talent” Carroll (1983, p.608). -  has 
evolved since the 1950s and rapidly multiplied in the 1970s (Carroll, 1999). In 2003, Schwartz 
and Carroll (2003), in order to better define CSR elements, developed a three-domain 
conceptualization. It includes economic, legal and ethical obligations, joining the fourth 
dimension of philanthropy into the ethical component. 
 The emergence of CSR can be attributed to the Stakeholder Theory, as defended by 
Pirsch et al (2007). Developed by R.Edward Freeman, Stakeholder theory is related to 
organizational management and business ethics. Many scholars have tried to integrate the 
ethical perspective of CSR in the practical, managerial orientation of stakeholder theory (Mele 
2008; Parmar et al 2010; Windsor 2006). Nevertheless, both researchers on CSR and 
researchers on Stakeholder Theory are prone to defend that both topics are not quite the same. 
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The delimitation between them is explained by the differences in CSR obligations to the overall 
society and the responsibilities of business to create value (Berman et al 1999; Freeman and 
Liedtka 1991). 
 Financial economists are mainly interested in the financial impact of CSR in profit-
seeking companies. (Pour, B. et al, 2014). Several studies suggest that CSR has a positive 
impact not only on financial performance but also on the image of companies (e.g: Barnett and 
Salomon, 2006; Ruf et al., 2001). Nevertheless, others argue that due to the dependency that 
some industries have on certain stakeholder groups, the way their financial performance and 
corporate image can be affected considering social and or environmental negative changes, 
enhances the relevance of applying CSR measures.(e.g.: Hoepner et al., 2010; Martin L. Hirsch, 
2008; Servaes et al., 2013).  
The pharmaceutical industry is among these industries, due to the area in which it 
operates. This industry, which is constantly under scrutiny, is key for the European economy. 
In 2011, Europe was the second largest market for pharmaceutical sales, with a market value 
of €228.1 billion. The industry employed 660,000 people and had an international trade surplus 
of €48.3 bn (Source: EFPIA).1 There are not many other sectors that are able to match the 
contribution this sector offers regarding investment in R&D, trade balance and creation of 
skilled employment. Economically, the European pharmaceutical industry is seen as the world 
leader. As such, it will be the industry analyzed in this study.  
 I assess whether implementing CSR measures is associated with an increase in financial 
performance of highly pressured firms. By highly pressured firms I mean, firms that due to the 
sensible nature of their business are constantly under pressure to make morally compromised 
choices. As such, firms where their business may significantly affect lives - human or animal 
- (pharmaceutical industry, tobacco companies, among others).  
In this project I estimate a multivariate model in order to measure the level of impact 
of CSR measures on the financial performance of firms in the pharmaceutical industry. This 
way, I perform analyses focusing on the pharmaceutical industry that is considered highly 
pressured by stakeholders.  
Using data from Bloomberg and companies’ annual reports, the objective of this master 
thesis is to prove the impact of CSR measures on the financial performance of firms in the 
European pharmaceutical industry. To do so, three hypothesis are developed. As stated before 
and further developed during this paper, nowadays there is still some conflict between scholars 
                                                        
1 European Federation of Pharmaceutical Industries and Associations 
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regarding the impact of CSR measures in the financial performance of a company. Besides 
this, there is also a discussion regarding the influence of the time horizon in the same impact. 
Some scholars (Berman et al. 1999, Inoue and Lee 2011), defend that the impact of CSR 
measures affect differently the financial performance of a company during the short-term and 
the long-term. Nevertheless, there is still some controversy with scholars defending different 
results in the same time horizon.  
Based on what was stated above, my first two hypothesis were developed. First of all, 
I will run a multivariate model in order to prove CSR measures do not have a significant 
positive impact in the financial performance of a company in the short time. I will use, as a 
dependent variable, Return on Assets (ROA). ROA is seen as an accounting-based measure 
that explains how efficient a company is in using its assets. My second hypothesis state that 
CSR measures have a significant positive impact in the financial performance of a company in 
the long-time. As the dependent variable I will use Tobin’s Q that is defined as the evaluation 
that is made by the investor considering the potential of the company to generate future profits.  
My third hypothesis was developed considering that prior literature defends that, 
depending on the industry where the company operates, CSR measures may impact differently 
the financial performance of a company. Moreover, industries that have a closer relationship 
with the overall environment and the stakeholders, are affected differently by the CSR activities 
employed. As such, I state that CSR measures positively affect the financial performance of 
sensitive firms.  
In order to perform this study, I extracted from Bloomberg the following variables: 
market value of equity, total assets, total liabilities, return on assets, annual sales, R&D 
expenditures and year of foundation, and it will cover the firms in the chosen pharmaceutical 
industry. In order to measure CSR, I used company’s annual reports and I assess this via content 
analysis, which is a widely used method in the analysis of non-financial reports. 
I used a sample of 22 European pharmaceutical companies. The time period under study 
is from 2010 to 2013 (four fiscal years).  
It is important to mention that the results obtained in this study have to be interpreted 
with care, due to the limitations attached to it. Main limitations concern source of the data and 
sample size, and as such, can affect very significantly the conclusions taken from the results 
obtained.  
With this study, I contribute to the literature by analyzing how CSR measures impact 
the financial performance of a specific industry (pharmaceutical) in a specific continent 
(European). Most of the studies are based on US companies’ or in a specific country. Also, 
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most of the studies include companies from different industries, or more than one industry in 
the same study. 
 
Literature Review 
The European Union states that CSR has to be seen as a behavior of the business that 
goes beyond the legal requirements (European Commission, 2011). It defines CSR as a social 
contract, between the company and the society which obliges the company to, when making 
decisions, thinking about the overall society. (European Commission, 2011) Furthermore, 
companies have their own ideologies on social responsibility and what it means to act socially 
responsible. This, in the business world, revolves around creating shared value.  
 Sprinkle and Maines (2010) mention several motivations for companies to incorporate 
CSR activities. First, by being involved in CSR activities, a company is automatically protected 
from negative publicity and also from harsh measures from Non-Governmental Organizations 
(NGOs). NGOs are seen as a key stakeholder when considering CSR strategies, since they are 
involved in activities such as awareness raising, both to the general public and to policymakers. 
Second, investors are more willing to invest in companies that employ CSR practices. Finally, 
customers are also more willing to embrace in a customer relationship with companies that 
employ CSR practices. Carroll and Shabana (2010) find that consumers prioritize social 
responsiveness and minimize financial benefits. Employees also feel more attracted to 
companies that behave in a social responsible manner. In fact, Albinger and Freeman (2000) 
find that job-seekers, when aware of CSR practices, feel more willing to accept a job in a 
company that employs such practices. Also, Flynn (2005) shows that employees reward CSR 
practices linked to their job due to the feeling of engagement in being productive. In line with 
this, Bashir et al. (2012) also find that employees feel some comfort with social responsible 
firms, therefore increasing their productivity. The economic motivation is also important. CSR 
can be a way of reducing production costs. Sprinkle and Maines (2010) find that the cost of 
operations can be reduced significantly if a company increases efficiency by becoming focused 
on reducing wastes - environmental focus. Other researchers show that by developing 
environmentally friendly products, firms can reduce costs and attract and retain new customers 
(Bauman & Skitka, 2012).  
 Due to all these reasons, CSR activities can be a way of creating and developing 
strategic resources. By building a positive reputation and developing a good corporate image, 
companies are able to institute convenient stakeholder relationships, which will in the end help 
the firm to charge more for their products, attract and retain customers, employees and capital 
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investors (Wang & Bansal, 2012).  Petersen and Vredenburg (2011), present a study where 
they analyze if it is important for institutional investors to invest in companies that are social 
responsible. More than concluding that institutional investors are prone to invest in social 
responsible firms, they also conclude that there are CSR variables that impact not only the 
decision of investing, but also the decision to keep the shares later on - this has an impact on 
the capital market’s valuation of the firm.  
 Researchers have assessed the relationship between CSR and financial performance, 
with mixed findings. Margolis and Walsh (2003) review 127 studies and find that 54 find 
evidence of a positive relationship, 7 conclude there is a negative relationship, and 28 present 
no significant association. These findings can be categorized into three major groups. The first 
one supports the stakeholder theory, developed by Freeman (1984). This view purposes that 
the survival of a firm is dependent, not only on the maximization of profit, but also on the 
social performance of the company (Kang et al., 2010). Several researchers like Anderson and 
Frankle (1980), Shane and Spicer (1983) and Spicer (1978) obtain results that support the latter 
(Khanifar et al., 2012). On the opposite side, there is the view which believes that CSR has a 
negative relationship with financial performance. This view is aligned with the idea developed 
by Friedman (1970), who believes managers are only obligated to increase the profit of the 
firm, and thus, meaning that the company is only responsible to increase the return to its 
shareholders. Vance (1975) as well as Wright and Ferris (1997) produced findings that are in 
line with this theory (Barnett & Salomon, 2012).  In the final group, researchers argue that 
there are too many parameters difficult to measure and that may end up intertwining relations, 
which in the end leads to not being able to drive precise conclusions regarding the relationship 
between CSR and financial performance (e.g.: Kang et al., 2010).  
 Financial performance can be measured in terms of short-term or long-term 
profitability. While the first one measures abnormal returns, the second one uses accounting or 
financial measures of profitability. Researchers find mixed results, when comparing 
conclusions based on these different ways of measuring return (Tsoutsoura, 2004). This can be 
a consequence of methodological concerns (Margolis & Walsh, 2003) or even model 
misspecification (Servaes & Tamayo, 2013), as it is still unclear the channels by which CSR 
affects firm value. Although most of theoretical models assume that there is a direct link 
between CSR and firm value, Barnett (2007) relies on the idea that the impact of CSR on firm 
value is dependent on the capacity of CSR to influence stakeholders.  
 Scholars found that the impact of CSR depends on several characteristics of the firm. 
Factors such firm’s size, R&D, market conditions, age and diversification, have a considerable 
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impact on how CSR will in the end affect the financial performance of the firm (McWilliams 
& Siegel, 2001). Another important aspect is industry. Studies have confirmed that the impact 
of CSR activities varies with the industry of the company. Inoue and Lee (2011) dedicate their 
study to analyze the impact of CSR in different companies within the tourism industry, but 
comprising different sub-industries: casino, hotel, airline and restaurant. The results of their 
study indicate that the financial impact is different across sub-industries. Kang et al. (2010) 
also found the supporting results to this view – however, in this study the hospitality industry 
was the one under scrutiny. Scholars defend that some industries, due to more challenging 
economic and social pressures that have to be accounted for, are facing demands to respond 
positively to the test of CSR (Khanifar et al., 2012). Hoepner et al. (2010) defend that the 
heterogeneity across industries is mainly explained by four concepts: (i) dependence on 
individual stakeholder groups, (ii) proximity to the end consumers, (iii) the potential an 
industry shows for social practices, (iv) environmental damage and the level of product/service 
differentiation.  In the pharmaceutical industry CSR issues are very sensitive, as they include 
patient access to healthcare, patents protections, and affordability, among others (Khanifar et 
al., 2012). According to Hoepner et al. (2010) the healthcare industry’s CSR practices improve 
significantly the financial performance of companies. Thus, in this study, I focus on the 
pharmaceutical industry. 
 
Hypothesis 
 Based on the previous literature review I develop three hypotheses. Although there are 
some mixed results regarding the impact of CSR in the financial performance of a company, a 
considerable percentage of the studies are in favor of a positive relationship between the two 
variables. However, scholars have found that CSR has a different impact on the financial 
performance of the company when the time horizon of the analysis varies. Berman et al. (1999) 
support the idea that on the short term, only some CSR dimensions can positively impact the 
financial performance of a company. This vision is also supported with the theory supported 
by Inoue and Lee (2011). A variety of studies, to measure the impact of CSR on short-term 
profitability, apply return on assets (ROA). Kang et al. (2010), using this measure, are only 
able to find a positive relationship for one out of the four hospitality industries (hotel, casino, 
restaurant and airline companies). Based on these findings, I state the first hypothesis as 
follows: 
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Hypothesis 1: CSR activities do not have a significant positive impact on the financial 
performance of a company in the short-term. 
 
𝐶𝑆𝑅𝐷 =  𝛼 +  𝛽1 𝑅𝑂𝐴 +  𝛽2𝐿𝐸𝑉𝐸𝑅𝐴𝐺𝐸 + 𝛽3𝑆𝐼𝑍𝐸 + 𝛽4𝐴𝐺𝐸 +  𝛽5𝑅&𝐷 
 
 When considering long-term financial performance, Inoue and Lee (2011) show that 
long-term financial performance is affected differently considering each dimension of CSR. A 
positive link between each dimension of CSR on the long-term financial performance was 
found by several studies. As such, the second hypothesis is stated as follows: 
 
Hypothesis 2: CSR activities have a significant positive impact on the financial performance 
of a company in the long-term. 
 
𝐶𝑆𝑅𝐷 =  𝛼 +  𝛽1 𝑇𝑜𝑏𝑖𝑛
′𝑠 𝑄 +  𝛽2𝐿𝐸𝑉𝐸𝑅𝐴𝐺𝐸 + 𝛽3𝑆𝐼𝑍𝐸 + 𝛽4𝐴𝐺𝐸 +  𝛽5𝑅&𝐷 
 
 Prior literature confirms that depending on the industry a firm is operating, CSR 
activities and dimensions can have different impacts on financial performance. Moreover, 
industries that are seen as more sensitive due to the relationship with the overall environment 
and the stakeholders, are affected by CSR activities very differently. In these companies, CSR 
activities have a much higher impact on their financial performance. The set of firms that I 
consider to be included in a sensitive industry consists of pharmaceutical companies. Based on 
the literature, the third hypothesis is stated as follows: 
 
Hypothesis 3: CSR activities have a higher impact on the financial performance of sensitive 
firms. 
 
 This hypothesis will be tested by comparing the results I obtained with previous studies 
done using similar methodologies in other industries.  
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Methodology 
Measuring Corporate Social Responsibility  
For the purpose of this study, CSR will work as the main independent variable.  I assess 
this via content analysis. 2Content analysis is a widely used method in the analysis of non-
financial reports. (Giannarakis et al., 2011). Guthrie and Abeysekera (2006) define that content 
analysis corresponds to the technic of codifying qualitative and quantitative into pre-defined 
categories. This method allows researchers to obtain patterns in recording and presenting 
information. In a similar way, Krippendorff (2004) defends that content analysis allows making 
inferences, since it legitimates the transformation of raw information into usable one. To better 
understand content analysis, it is important to consider what it means to have qualitative and 
quantitative items.  
Possible quantitative items include number of pages, sentences and words to discuss 
social responsibility in a company’s annual report. In the end the quantitative approach will 
transform such items into quantitative statistical data. (Giannarakis et al., 2011). The 
quantitative approach can have a considerable drawback since it might happen that those pages 
include graphs with no relevant information on social activities, or that sentence and word 
counting miss relevant information presented in tables and graphs (Singh, 2014). In the 
qualitative approach we first identify environmentally relevant issues and only after are the 
environmental disclosures analyzed, through the use of a score. Qualitative approach is more 
connected to analyze the intentionality of elements and parts of texts and the implications they 
have.  
Content analysis also has drawbacks. Cochran & Wood (1984) state that this method is 
merely a snapshot of what the firm claims to be and as such skepticism has to be incorporated 
when analyzing the data obtained. Nevertheless, it is a relatively easy method to apply, since 
it is very objective and allows the analysis of considerably big sizes of information. Patten and 
Crampton (2004) classify content analysis as the most straightforward method to identify if a 
company presents social responsible information in their official documents or not.  
                                                        
2 The most common and more famous method to measure CSR is reputation index in the Kinder, Lydenberg, 
Domini (KLD) database, developed by Waddock and Graves (1997). This dataset contains an index based on an 
annual analysis of the environmental, social, and governance performance of companies rated by KLD Research 
& Analytics, Inc. In order to achieve a rating, 80 indicators in 7 major qualitative issue areas are analysed 
(Community, Corporate Governance, Diversity, Employee Relations, Environment, Human Rights and Product). 
Involvement by the companies in controversial business areas is also considered. In 2003 KLD, which in 1991 
was only able to provide a table with data from only 650 companies, reached a universe of the largest 3000 US 
companies by market capitalization. As such, and since this study is focused on the European pharmaceutical 
industry, this method is not valid. 
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Although content analysis is used throughout a significant number of studies, the unit 
of analysis has varied considerably among them. As Krippendorf points “In content analysis, 
three kinds of units deserve distinction: sampling units, recording/coding units, and context 
units” (p.97, 2004). To him, sampling units are defined as “units that are distinguished for 
selective inclusion in an analysis… Content analysts must define sampling units so that (a) 
connections across sampling units, if they exist, do not bias the analysis; and (b) all relevant 
information is contained in individual sampling units, or, if it is not, the omissions do not 
impoverish the analysis” (pp. 98-99). Adams et al. (1998) state that Annual reports are seen as 
the most important source of information regarding a company overall activities. A massive 
part of CSR literature has used annual reports as sampling unit (O’Dwyer, 1999). Therefore, I 
also base my analysis in the annual reports of the chosen companies. 
 Krippendorf (2004) defines coding units, as “Whereas sampling units are distinguished 
for inclusion in or exclusion from an analysis, ideally in a way that acknowledges natural 
boundaries, recording units are distinguished to be separately described or categorized. Thus 
recording units are typically contained in sampling units, at most coinciding with them, but 
never exceeding them” (pp. 99-100). A considerable number of CSR studies chose to employ 
words as recording units (Campbell et al., 2003; Deegan and Gordon, 1990; Gao et al., 2005; 
Wilmshurst and Frost, 2000) (Vourvachis). For Zeghal and Ahmed (1990) inconsistencies are 
avoided using word count, since words are the smallest unit of analysis. Due to this reason it 
provides maximum robustness in quantitative disclosure. Wang and Bansal (2012) applied 
content analysis on their study where they analyzed text published on all the introductory 
websites of the firms being scrutinized. To do so, they based their study on discrete CSR items 
and identified CSR keyword and the frequency at which they occurred. I follow their 
methodology.  
 I measure CSR disclosure through a keyword count method, using a free version of 
Atlas-ti 7, which is a software used for qualitative data analysis. This software allows me to 
assess the extension of CSR reporting in a firm’s annual report. Firstly, the number of times a 
pre-defined CSR keyword (Appendix 1) appears in my sample unit will be calculated. The 
CSR keyword used for this study is the same one used by Wang and Bansal. Following the 
same approach of Wang and Bansal (2012), I do not distinguish different forms of the same 
word or count different tenses of the same word separately. In order to have robustness in the 
analysis, a manual check is performed on a sample of the data to make sure that the identified 
keywords are connected with CSR. After discovering the frequency of each distinct keyword, 
the level of CSR disclosure is estimated through the following formula; 
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𝐶𝑆𝑅𝐷 =  
(∑ 𝑇𝑖)
𝑁
𝑖=1
𝐾
 
 
where N is the number of CSR keywords in the sample unit, 𝑇𝑖 is the respective frequency and 
K is the total number of keywords presented in the annual report. According to Wang and 
Bansal (2012), it has been observed that larger firms show a tendency to have more CSR 
keywords when compared with smaller firms. As such, the total number of words in the annual 
report divides the sum of total CSR keywords.  
 
Financial Performance Measures 
As explained above, financial performance can be measured considering short-term and 
long-term. For the short-term profitability, the dependent variable chosen is ROA and for the 
long-term profitability I use Tobin’s Q, following the methodology of Barnett & Salomon 
(2012) and Inoue and Lee (2011). ROA is seen as an accounting-based measure that measures 
how efficient a firm is in the usage of its assets, during a period of time. It is estimated by using 
operating income before interest expense, depreciation and amortization over total assets 
(Inoue & Lee, 2011). Tobin’s Q is defined as the evaluation that is made by the investor 
considering the potential of the company to generate future profits. In other words, it is seen 
how the market perceives a company’s value. Tobin’s Q is estimated by adding market value 
of equity to liabilities divided by total assets (Inoue & Lee, 2011). The formula is expressed 
as:  
 
𝑇𝑜𝑏𝑖𝑛’𝑠 𝑞 =  (𝑀𝑉𝐸 +  𝑃𝑆 +  𝐷𝐸𝐵𝑇)
𝑇𝐴
 
 
where MVE is obtained by a firm’s stock price multiplied by the number of its common stocks 
outstanding; PS is the liquidating value of a firm’s outstanding preferred stock; DEBT is the 
value of short-term liabilities net of a firm’s short-term assets plus the book value of its long-
term assets; and TA is the book value of a firm’s total assets. This is the simplified version of 
the original Tobin’s expression (1969), which was developed and validated by Chung and 
Pruitt (1994). To simplify even more, Klapper and Love (2004) defined Tobin’s Q as being 
simply market value of equity plus total liabilities divided by total assets. For the purpose of 
this study I will use Tobin’s Q as defined by Klapper and Love (2004). 
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Control Variables  
Financial performance is not only affected by CSR, and as such control variables have to be 
considered in the model. Following McWilliams and Siegel (2001) four control variables are 
included: SIZE, AGE, R&D and LEVERAGE.  
SIZE is important since bigger firms tend to be more prone to adopt CSR policies and practices. 
(McWilliams and Siegel, 2001 and Waddock and Graves, 1997). Following the approach used 
in previous studies, size is estimated as the natural log of annual sales. 
Wang & Bansal (2012) suggested that more recent firms are not able to realize economies of 
scale from the CSR investment made, as older firms do. As such, AGE is a factor to be 
considered. Firm age is estimated by summing the numbers since the firm’s creation.  
Due to the fact that R&D investment may result in CSR-related process and product 
innovations, it is relevant to analyze this variable. Since R&D tends to end up in the majority 
of times in product innovations (Link, 1982), it will be measured by a ratio of R&D 
expenditures to total sales. (McWilliams and Siegel, 2001). 
LEVERAGE is included in my model to avoid the effect of firm-specific capital structure in 
the relationship between CSR and financial performance. Following the methodology of both 
McWilliams and Siegel (2001) and Waddock and Graves (1997), LEVERAGE is estimated by 
dividing firm’s total debt by the firm’s total assets. It makes sense to control for LEVERAGE, 
since it is expected that high leverage companies will behave differently concerning CSR 
investment due to different risk levels involved in CSR investment (Waddock and Graves, 
1997).  
 
Sample 
The pharmaceutical industry, which is constantly under scrutiny, is key for the 
European economy. In 2011, Europe was the second largest market for pharmaceutical sales, 
with a market value of €228.1 billion. The industry employed 660,000 people and had an 
international trade surplus of €48.3 bn (Source EFPIA). There are not many other sectors that 
are able to match the contribution this sector offers regarding investment in R&D, trade balance 
and creation of skilled employment. Economically, the European pharmaceutical industry is 
seen as a world leader. Since 1985, the European Commission strives to achieve a single market 
for this industry by guaranteeing direct access to medical products, providing high quality 
information to the public, and to make sure that the production and selling of the products is 
done with the highest quality and safety standards. This industry is extremely relevant not only 
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by its economic power, but also because it provides high-quality employment and a 
considerable amount of investment in research and development for the public health. Finally, 
this industry also promotes the development of research and innovation, which will translate 
in a more competitive economy. As such, it is seen as a crucial industry in Europe. The sample 
of this study includes the largest pharmaceutical firms in Europe, which are identified via their 
market capitalization, and also smaller firms. 
There are much more pharmaceutical companies operating in Europe, however the 
focus of my study is in European pharmaceutical companies and several operating in Europe 
have their headquarters in other continents which leads to a much lower sample. Another 
constraint in my sample size is that some are private companies, meaning that it is not possible 
to have access to their financial data, constraining even more my sample size. Adding to this 
issue, some of them have no published annual reports. Due to these reasons, I was only able to 
have a sample of 22 pharmaceutical companies, since the three requisites mentioned before 
excluded a considerable amount of pharmaceutical companies from the study.  
The set of firms analyzed include the 22 pharmaceutical companies indicated in 
Appendix 2. The time period under study is from 2010 to 2013 (four fiscal years). This period 
is coincident with the Eurozone Crisis, which may have had a negative impact on the financial 
health of the companies in the sample. However, studies have shown that, except for the period 
of 2009-2010, CSR performance before and during financial crisis increased significantly 
(Giannarakis and Theotokas, 2011). This effect is explained by the fact that companies need to 
differentiate themselves in order to survive in this harsh environment. As such, CSR strategies 
and initiatives can be seen as a good strategy (Thomé, 2009). Companies start to understand 
that instead of seeing CSR as a threat due to its high costs – which in a crisis situation can be 
very difficult to deal with – they should see it as an opportunity to differentiate and gain 
competitive advantage (Giannarakis and Theotokas, 2011).  
The source of the data used for this study is Bloomberg, from where I downloaded the 
following variables: market value of equity, total assets, total liabilities, return on assets, annual 
sales, R&D expenditures and year of foundation, and it will cover the firms in the chosen 
pharmaceutical industry (Appendix 2).3 
 
 
                                                        
3 Missing values that Bloomberg could not provide were directly looked-on the companies’ annual reports.  In 
order to ensure the reliability of the data, a sample was compared with the annual reports values. 
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Results 
 
Descriptive Statistics 
 Table 1 illustrates a descriptive summary of all variables under analysis in the study. 
𝐶𝑆𝑅𝐷, my main variable, has a mean value of 0.01, which means that, on average, for every 
1000 words published on the annual reports, 10 are CSR keywords. Singh (2014), with a similar 
study performed in UK firms, found that the industry of crude petroleum has a mean value for 
CSR disclosure of 0.005 (0.5%). This result was considered very low comparing to the ones 
obtained for the mining and crude petroleum, which have achieved results of 0.008 (0.8%) and 
0.007 (0.7%), respectively. My result was considerably higher than all of the three, specially 
comparing with the UK pharmaceutical industry. This may happen since I am considering 
pharmaceutical companies of all Europe and not only a specific zone like in its study. It may 
also be a cultural difference, with companies being more prone to disclose CSR related matters 
in their annual reports, than British companies. 
 The pharmaceutical industry has persistently been one of the most profitable industries 
in the US. By 2005, Forbes magazine reported pharmaceutical companies in the US presented 
an average ROA of 10.3% compared with the overall industry average of 4.3. Nevertheless, 
researchers defend that this value is misrepresented. This is explained by the fact that standard 
accounting measures overstate true returns to R&D-intensive industries – as the pharmaceutical 
industry – making it difficult to compare with other industries. R&D spending is treated, by 
almost all accounting measures, as deductible business expense, instead of considering it a 
capitalized investment. The intangible assets generated by R&D (i.e. accumulated knowledge, 
patents, and new research capabilities) increase a company’s asset base. (Source: Research and 
Development in the Pharmaceutical Industry: A CBO Study). From 2010-2014, the industry 
average in Europe was 8.6%. (Nesic et al, 2014). My results present an average ROA of 8%. 
Comparing with the 2005 result in the US, it is comprehensible that during a crisis period ROA 
decreases, and it goes in line with the industry average estimated by other researchers.  
 Tobin’s Q is, on average, 2.18. Tobin’s Q is a measure that represents the ratio of the 
market value of a firm’s existing shares to the replacement cost of the firm’s physical assets. 
When the ratio is higher than one, it is sensible to increase additional investment in the firm, 
since the profits that are generated exceed the cost of the firm’s assets. It is important to 
consider that Tobin’s Q in the pharmaceutical industry is strongly affected by the intangible 
assets of the firm. Mahlich (2007), discovered that in Japanese pharmaceutical companies’ 
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while the patent stock had the expected positive impact on a firm's Tobin's Q, scientific journal 
publications were negatively correlated with a firm's market value. The result obtained was 
explained by the possible path dependencies that aggravate the diversification of a firm’s 
knowledge base. Bracker and Ramaya (2011) defend that there is a strong, curvilinear 
relationship between R&D intensity and Tobin's Q. Adding to this, the impact of R&D intensity 
on Tobin's Q changes significantly based on key characteristics of the firm. Specifically, R&D 
intensity appears to offer greater benefits to larger firms, firms in industries that are research 
intensive, and high-growth firms (Bracker & Ramaya, 2011). 
 Now I consider the control variables. R&D expenses relative to total sales are on 
average 12%. In the US, R&D intensity in the pharmaceutical industry rose from 12% in 1970 
to 19% in the late 1990’s. By 2006 all the top leaders share the same grounds in spending in 
R&D with an average of 15%. (Ayoub & Qadoumi, 2007). Nevertheless, my value presents a 
very big gap between minimum and maximum. For such an innovative industry, the average 
value was expected to be much higher, and it was not expected that both Galenica (2010 and 
2011) and Alliance Pharma (2010, 2011, 2012 and 2013) presented no investment on R&D. 
From the late 90’s until 2006, R&D spending decreased considerably, and with the Eurozone 
crisis that started in 2010, it is acceptable that R&D levels reach lower levels than when the 
economy is prospering. Nevertheless, compared with other industries, the pharmaceutical 
industry presents very high levels of R&D spending relative to the level of sales.  The average 
age of firms is 64, meaning that most of the companies in this industry are very well established 
in the market, and possess very deep knowledge of how it works and how to access it. The 
pharmaceutical industry shows an average for leverage of 0.28, which means that the long-
term debt for the industry falls short of its total assets by 28%. Usually, pharmaceutical 
companies present low leverage ratios. (Ross, et al, Business Finance 10e by Pearson). 
MacKay and Phillips (2005) study found that financial leverage is higher in concentrated 
industries than in competitive industries. 
 
Pearson’s Correlation Analysis 
Table 2 – Pearson’s Correlation Analysis, in the Appendix, exhibits Pearson’s correlation 
analysis for this study. The dependent variable of interest, CSRD is significantly and positively 
associated with SIZE, but not with Tobin’s Q and ROA. As such, none of the measures of 
financial performance are significantly correlated with CSR, in this initial analysis. One can 
also see that the control variables SIZE, AGE, R&D and LEVERAGE have significant 
correlations between them. This may induce us to expect to have the presence of 
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multicolinearity in the model. Colinearity implies that two variables are near perfect linear 
combinations between them. This may lead to the coefficients become unstable and the 
standard errors get considerably inflated. As such, I will inspect the variance inflation factors 
(VIF). As a rule of thumb, a variable whose VIF is greater than 10 may need further 
investigation. Considering Table 5, in Appendix 4, the values of VIF are quite acceptable – all 
of them are considerably lower than 10 – as such there is no multicolinearity in the model.  
 
Regression Analysis 
Hypothesis 1: CSR activities do not have a significant positive impact on the financial 
performance of a company in the short-term. 
 
𝐶𝑆𝑅𝐷 =  𝛼 +  𝛽1 𝑅𝑂𝐴 +  𝛽2𝐿𝐸𝑉𝐸𝑅𝐴𝐺𝐸 + 𝛽3𝑆𝐼𝑍𝐸 + 𝛽4𝐴𝐺𝐸 +  𝛽5𝑅&𝐷 
 
Based on the results presented in Table 3, there is no significant positive correlation of CSR 
with ROA, meaning that CSR activities do not have a significant positive impact on the 
financial performance of a company in the short-term. As such hypothesis 1 is supported by 
my results. 
 
Hypothesis 2: CSR activities have a significant positive impact on the financial performance 
of a company in the long-term. 
 
𝐶𝑆𝑅𝐷 =  𝛼 +  𝛽1 𝑇𝑜𝑏𝑖𝑛
′𝑠 𝑄 +  𝛽2𝐿𝐸𝑉𝐸𝑅𝐴𝐺𝐸 + 𝛽3𝑆𝐼𝑍𝐸 + 𝛽4𝐴𝐺𝐸 +  𝛽5𝑅&𝐷 
 
Based on Table 4, it is possible to conclude that there is no significant correlation, at a 5% 
confidence level, between Tobin’s Q and CSR disclosure. As such, it is not possible to prove 
hypothesis 2, meaning that, with the results I obtained, CSR activities do not have a significant 
positive impact on the financial performance of a company in the long-term. 
 
Hypothesis 3 
In order to measure the impact of CSR disclosure on the pharmaceutical industry, the 
coefficients have to be taken into consideration. Considering ROA, I obtained a coefficient of 
-0.010 indicating that the pharmaceutical industry suffers a negative impact from CSR 
disclosure on the short-term profitability. On the other hand, Tobin’s Q obtains a value of 
0.011, which indicated a positive impact from CSR disclosure on the long-term profitability. 
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Since, I only choose to use data from the pharmaceutical industry I will compare my results 
with a similar study in order to reach a conclusion. Singh (2014) ran a similar test on three 
different industries (crude petroleum, mining metal and pharmaceutical). Considering short-
term profitability, the industries of crude petroleum and mining metal obtained values of -0.218 
and -0.201, which was considerably different from the value that I obtained for the 
pharmaceutical industry. Also, Singh (2014) obtained, for the UK pharmaceutical industry a 
value of, 0.008 that is also different from the one I obtained, meaning that geographic areas 
can also affect the impact of CSR disclosure on the financial performance. Considering the 
long-term financial performance Tobin’s Q obtained for the industries of crude petroleum, 
mining metal and pharmaceutical -0.029, -0.045 and 0.022 respectively also all very different 
from the ones I obtained.  
Based on this comparative analysis, I can affirm that CSR affects different industries at 
different levels.  
 
Conclusion and limitations 
 
CSR analysis is one of the more sensitive topics on the current days. The ambiguity of 
it in the empirical studies has given rise to an enormous discussion between researchers. Due 
to the increase on competition throughout all industries, organizations have becoming more 
interested in finding new ways of gaining advantage over their competitors in order to achieve 
better financial performance. Theoretically, a way to do so is by engaging into CSR activities.  
My study is to evaluate if, in the European pharmaceutical industry, the implementation of 
CSR activities actually affected the financial performance of firms, considering both the short-
term and the long-term.   
The empirical results obtained suggest that CSR does neither affect the short-term 
financial performance of a company, nor the long-term financial performance. The results 
obtained for the short-term financial performance, are consistent with prior studies analyzed in 
the literature review that claims no immediate financial and economic benefits of implementing 
CSR activities. On the opposite, for the long-term financial performance, it was expected, 
based on prior literature, to have achieved a positive link between CSR and long-term financial 
performance, measured by Tobin’s Q. Based on the results achieved, I can conclude that other 
factors influence whether or not CSR influences long-term financial performance of a 
company. Based on a comparison analysis, I was also able to prove my third hypothesis and 
confirm that different industries are differently affected by CSR.  
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The results obtained in this study have to be interpreted with care, due to the existence 
of limitations. My main limitations are concerned with the sources of the data and also with 
the sample size. First of all, the presence of multicollinearity may be a result of the sample 
being too small. By having to remove some control variables from the model, in order to fix 
the multicollinearity problem, it may have ended up to affect negatively the quality of the study. 
Also, I only used 4 years of observations, meaning that the power of prediction may be 
corrupted. Selecting the appropriate sample size is crucial when designing a successful study. 
If the study shows insufficient sample size, the statistical power to detect important and 
consequential effects is corrupted and it may end up producing reckless answers and 
unpredictable results. (Guo Y. et al, 2013). In other words, the power of predicting future 
values based on prior years will not be effective and generalizations will not be achievable. If 
the sample size was bigger, either with more pharmaceutical companies or more years in the 
study, some correlations may have turned statistically significant, affecting the conclusions 
taken.  
Another limitation to the study is the data sources and the software used to perform 
content analysis. First of all, although annual reports are seen as a reliable source for CSR 
activities, it presents a lot of limitations discussed above. Moreover, the analysis I performed 
was only partial, and the software is not flawless. In other words, I did not read entirely the 
annual reports and as such, the calculation of the dependent variable is biased. Also, the 
software used has some flaws. One thing important to understand is that computers are not able 
to understand or discern the meaning of words or constructs, which affects the analysis, since 
some words have more than one meaning. (Smit, B., 2002).  
One important issue to consider, is that I am considering the level of CSR of a company based 
on the amount of CSR keywords it shows on its annual report. This can be a very flaw proxy 
compared to the reality of what truly happens. A company may claim to be engaged in plenty 
activities that it is actually not, being only “show-off” for the stakeholders.  
I challenge future researchers to continue this research including more data and also to find 
better sources of CSR information in order to increase the reliability of the study. Also, as 
discussed before, it might be interesting to compare industries across different 
regions/countries, since culture might also be a component that affects the relationship between 
CSR and financial performance.  
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Appendix 1 
CSR Keywords   CSR Keywords   CSR Keywords 
Accountability   Exceed   Power 
Biodegradable  Fair  Preservation 
Bio-fuel  Fundraising  Recycle 
Charity  Future  Renewable 
Community   Global warming  Responsibility 
Conservation  
GMO-free (genetically 
modified organisms)  Reuse 
Contamination  Green/Greener  Risk 
Corporate Citizenship  
HACCP (hard analysis 
and critical control 
points)  Safety 
Donation  Harmful  Security 
Downgrade  Hazard/Hazardous  Sponsor 
Drug-free  Health  Stewardship 
Earth  Honest  Surpass 
Ecosystem   Integrity  Sustainability/Sustainable 
Emission  ISO14001  Trans-fat-free 
Energy  Nature  Transparency 
Enrich  Non-invasive  Trees 
Environment  Nontoxic  Trust/trusted 
Equality  Organic  Waste 
Ethics   Philanthropy   Wellbeing 
Source: Wang and Bansal (2012) 
 
Appendix 2 
Name 
Astrazeneca Hikma 
Bayer Novo Nordisk 
GlaxoSmithKline Fresenius 
IPSEN Grifols 
Lundbeck Galenica 
NOVARTIS Almirall 
Orion Recordati 
ROCHE Meda AB 
Sanofi Dechra Pharmaceuticals 
UCB Sinclair IS Pharma 
Alliance Pharma Skyepharma 
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 Table 1 – Descriptive Statistics 
Variables  CSR D ROA Tobin's Q Leverage R&D % Sales Age Size 
N 88 88 88 88 88 88 88 
Mean .011 7.8% 2.184 28.867 12.4% 63.64 3.52 
Median .011 6.0% 1.665 22.263 14.0% 70.00 3.51 
Std. 
Deviation 
.00 .082 1.564 29.601 .086 36.37 1.03 
Variance .00 67.2 2.445 876.20 73.995 1322.67 1.06 
Minimum 0.00 -10.87% .5010 0.0 0.00% 13.00 1.45 
Maximum .02 35.80% 10.98 172.25 40.45% 150.00 4.92 
 
 Table 2 – Pearson’s correlation analysis 
 
  
 Table 3 – Hypothesis 1 Regression Results 
 
Table 4 – Hypothesis 2 Regression Results  
 
CSR D ROA Tobin's Q Leverage
R&D % 
Sales
Age Size
CSR D 1
ROA .184 1
Tobin's Q .055 ,582
** 1
Leverage -.125 -,251
*
,268
* 1
R&D % Sales .148 .049 .190 ,250
* 1
Age .200 .109 -.009 -,231
* .016 1
Size ,489
**
,387
** .090 -,298
**
,258
*
,429
** 1
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
Standardized 
Coefficients
B Std. Error Beta Lower Bound Upper Bound Tolerance VIF
(Constant) .005 .001 3.631 .000 .002 .008
ROA -1.153E-06 .000 -.003 -.025 .980 .000 .000 .824 1.214
Leverage 1.813E-06 .000 .015 .140 .889 .000 .000 .773 1.294
Size .002 .000 .493 3.977 .000 .001 .003 .603 1.658
Age -7.781E-07 .000 -.008 -.075 .941 .000 .000 .794 1.260
R&D % Sales 7.172E-06 .000 .018 .165 .870 .000 .000 .813 1.231
Unstandardized 
Coefficients
t Sig.
95,0% Confidence Interval 
for B Collinearity Statistics
Standardized 
Coefficients
B Std. Beta Lower Bound Upper Bound Tolerance VIF
(Constant) .005 .001 3.602 .001 .002 .008
Tobin's Q 8.371E-06 .000 .004 .037 .971 .000 .000 .892 1.121
Leverage 1.732E-06 .000 .015 .130 .897 .000 .000 .734 1.362
Size .002 .000 .492 4.151 .000 .001 .002 .662 1.511
Age -7.504E-07 .000 -.008 -.072 .943 .000 .000 .800 1.250
R&D % Sales 7.069E-06 .000 .017 .162 .872 .000 .000 .809 1.237
Unstandardized 
Coefficients
t Sig.
95,0% Confidence Interval 
for B Collinearity Statistics
